HUTCHMED shares are trading higher after the company and Takeda announced the publication of Phase III FRESCO-2 results in The Lancet, which showed fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer.
Portfolio Pulse from Benzinga Newsdesk
HUTCHMED and Takeda announced the publication of positive Phase III FRESCO-2 results in The Lancet, showing fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer.
June 16, 2023 | 6:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HUTCHMED shares are trading higher after positive Phase III FRESCO-2 results showed fruquintinib reduced the risk of death by 34% in metastatic colorectal cancer.
The positive Phase III FRESCO-2 results indicate that fruquintinib, a product developed by HUTCHMED and Takeda, has significant potential in treating metastatic colorectal cancer. This news is likely to boost investor confidence in HUTCHMED, leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100